Northland Securities Predicts MiMedx Group Q1 Earnings

MiMedx Group, Inc (NASDAQ:MDXG) – Equities researchers at Northland Securities decreased their Q1 2026 EPS estimates for MiMedx Group in a report released on Wednesday, February 4th. Northland Securities analyst C. Byrnes now anticipates that the company will post earnings of $0.00 per share for the quarter, down from their prior estimate of $0.02. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Securities also issued estimates for MiMedx Group’s Q3 2026 earnings at $0.04 EPS and Q4 2026 earnings at $0.05 EPS.

Several other research firms also recently weighed in on MDXG. Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 2nd. Mizuho reduced their price objective on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, December 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a report on Monday, December 29th. Finally, Lake Street Capital dropped their price target on MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 20th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, MiMedx Group has an average rating of “Moderate Buy” and an average target price of $10.67.

MiMedx Group Price Performance

MiMedx Group stock opened at $5.15 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.41 and a quick ratio of 3.95. The stock has a market cap of $762.72 million, a price-to-earnings ratio of 19.07 and a beta of 1.59. The firm has a 50-day moving average of $6.24 and a two-hundred day moving average of $6.76. MiMedx Group has a 1 year low of $4.89 and a 1 year high of $8.54.

Hedge Funds Weigh In On MiMedx Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. LSV Asset Management bought a new position in MiMedx Group in the fourth quarter worth about $360,000. Isthmus Partners LLC raised its stake in shares of MiMedx Group by 3.7% during the 4th quarter. Isthmus Partners LLC now owns 438,732 shares of the company’s stock worth $2,970,000 after acquiring an additional 15,469 shares in the last quarter. World Investment Advisors bought a new position in shares of MiMedx Group during the 4th quarter worth approximately $173,000. Swiss Life Asset Management Ltd purchased a new stake in MiMedx Group during the fourth quarter valued at approximately $173,000. Finally, Aprio Wealth Management LLC acquired a new stake in MiMedx Group in the fourth quarter valued at approximately $119,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.